Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Myeloproliferative Neoplasms: A Contemporary Review.

Slides:



Advertisements
Similar presentations
Verstovsek S et al. Proc ASCO 2011;Abstract 6500.
Advertisements

Myeloproliferative Neoplasms
Myeloproliferative Disorders / Neoplasms Intro for the Internist Satish Shanbhag MBBS, MPH Assistant Professor of Medicine and Oncology Johns Hopkins University.
Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Therapy.
APMG Pathologist, MD FCAP
Myeloproliferative Neoplasms 2015
The Efficacy and Safety of Continued Hydroxyurea Therapy versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind,
Real-World Assessment of Clinical Outcomes in Lower-Risk Myelofibrosis Patients Receiving Treatment with Ruxolitinib Davis KL et al. Proc ASH 2014;Abstract.
Myeloid Blastic Transformation of Myeloproliferative Neoplasms A Review of 112 Cases Presenter: Syed Jawad Noor, PGY3 Mentor: Meir Wetzler June 09, 2010.
The Chronic Myeloproliferative Disorders (MPD) A JENABIAN MD.
Complete Hematological Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon -2a (peg-IFN-2a) Therapy.
Good morning… My presentation is about Calreticulin and PMF
Changes in Quality of Life and Disease- Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial.
Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Cutaneous Lupus Erythematosus Disease Area and.
Date of download: 6/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Bacterial Coinfection in Influenza: A Grand Rounds.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Efficacy of Omeprazole for the Treatment of Symptomatic.
Date of download: 6/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Randomized Trial to Evaluate the Efficacy of Cognitive.
October 2014 Myeloproliferative Neoplasms Angela Fleischman Division of hematology/Oncology.
Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Duloxetine on Pain, Function, and Quality.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Allogeneic Stem Cell Transplantation for Acute Myeloid.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Insulin Therapy for Type 2 Diabetes Mellitus JAMA.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
Date of download: 11/13/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Stereotactic Radiosurgery Plus Whole-Brain Radiation.
Copyright © 1998 American Medical Association. All rights reserved.
Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2014 American Medical Association. All rights reserved.
Copyright © 2007 American Medical Association. All rights reserved.
Myeloproliferative Neoplasm (MPN) Clinical Trials Portfolio
Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2014 American Medical Association. All rights reserved.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2001 American Medical Association. All rights reserved.
Copyright © 2004 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Diagnostic algorithm for suspected primary myelofibrosis
Diagnostic algorithm for suspected essential thrombocythemia
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2004 American Medical Association. All rights reserved.
CCO Independent Conference Highlights
Copyright © 2006 American Medical Association. All rights reserved.
Myeloproliferative Neoplasm (MPN) Clinical Trials Portfolio
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2008 American Medical Association. All rights reserved.
Ann Intern Med. 2008;149(1): doi: / Figure Legend:
Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2017 American Academy of Pediatrics.
5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) as Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)1  
Myeloproliferative Neoplasm (MPN) Clinical Trials Portfolio
Copyright © 2004 American Medical Association. All rights reserved.
Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Ruxolitinib + Azacitidine in Newly Diagnosed or R/R, Intermediate- or High-Risk Myelofibrosis New Findings in Hematology: Independent Conference Coverage.
Combination Ruxolitinib + Sonidegib in Myelofibrosis
PERSIST-1: Pacritinib Improved Spleen Volume Reductions in Myelofibrosis vs Best Available Therapy CCO Independent Conference Highlights of the 2015 ASCO.
The JAK-STAT signal-transduction pathway
New Findings in Hematology: Independent Conference Coverage
Program Goals Case 1: Woman With MDS Risk: Cytogenetic Subgroups.
Chronic Myeloproliferative Neoplasms (MPN) Ph-negative
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Ayalew Tefferi, MD, Tiziano Barbui, MD  Mayo Clinic Proceedings 
Polycythemia Vera: A Comprehensive Review and Clinical Recommendations
Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia  Fabrice Usseglio, Nathalie Beaufils, Anne Calleja, Sophie.
by R. Coleman Lindsley, and Benjamin L. Ebert
Future Directions in Myelofibrosis: Implications of Emerging Approaches.
Pathogenesis of myeloproliferative neoplasms
Ayalew Tefferi, Pierre Noel, Curtis A. Hanson 
Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms  Janine Prick, Gerald de Haan, Anthony R. Green,
Sanger sequencing results
Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects
Presentation transcript:

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Myeloproliferative Neoplasms: A Contemporary Review JAMA Oncol. 2015;1(1): doi: /jamaoncol The 2008 World Health Organization (WHO) Classification of Chronic Myeloid Neoplasms Figure Legend:

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Myeloproliferative Neoplasms: A Contemporary Review JAMA Oncol. 2015;1(1): doi: /jamaoncol Practical Algorithm for Diagnosis of Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF) Figure Legend:

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Myeloproliferative Neoplasms: A Contemporary Review JAMA Oncol. 2015;1(1): doi: /jamaoncol Contemporary Treatment Algorithm for Polycythemia Vera and Essential Thrombocythemia a All patients with polycythemia vera should undergo phlebotomy to maintain a hematocrit of less than 45%. Figure Legend:

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Myeloproliferative Neoplasms: A Contemporary Review JAMA Oncol. 2015;1(1): doi: /jamaoncol Contemporary Treatment Algorithm for Primary MyelofibrosisDIPSS indicates Dynamic International Prognostic Scoring System; WT, wild type. a Outside clinical research, conventional drugs used for treatment of anemia include androgen preparations, prednisone, danazol, thalidomide, and, in the presence of del(5q), lenalidomide. Drugs used for treatment of splenomegaly and constitutional symptoms include hydroxyurea and ruxolitinib. In terms of clinical trials, we are currently most interested in potentially disease-modifying agents such as inhibitors of mutated isocitrate dehydrogenase protein and telomerase, as well as immune conjugates directed at leukemic stem cells. It is also important to confirm the potential value of another Janus kinase (JAK) inhibitor (momelotinib), currently in a phase-3 study, in improving anemia, in addition to its demonstrated efficacy in controlling splenomegaly and constitutional symptoms. Figure Legend: